Introduction
============

Non-small cell lung cancer (NSCLC) is among the leading causes of cancer death in the western world and increasing in many other countries. Survival of patients with locoregionally advanced disease (stage III) and metastatic disease has remained disappointing despite some gradual improvement \[[@B1],[@B2]\]. Patients with stage III disease differ with regard to primary tumour volume and proximity/infiltration to surrounding structures, extent of lymphatic spread, cancer biology, and host factors such as age, cardiopulmonary function and other comorbidity \[[@B3]\]. Treatment recommendations have to take into account these differences and stratify patients according to technical resectability, ability to tolerate high-dose radiotherapy and chemotherapy, and many more.

Many patients with inoperable stage III disease are candidates for combined modality chemo- and radiotherapy (RT). While concomitant administration might improve survival, parallel increases of toxicity have also been observed \[[@B1],[@B4]\]. The dilemma of simultaneous increases in efficacy and toxicity becomes even more difficult in elderly patients and those with considerable pretreatment weight loss, reduced performance status and comorbidity. Incorporation of novel agents might be advantageous in several ways. It might allow for administration of combined modality treatment in patients who are not candidates for established chemoradiation regimens and where RT alone results in unsatisfactory outcomes. Moreover, certain agents might be added on top of chemoradiation with the aim of further improving treatment results in patients who can tolerate aggressive approaches.

The theoretical solution of simply increasing radiation doses to high biologically effective doses (BED), ideally above the threshold of 100 Gy in 2-Gy fractions, which has been suggested by several groups \[[@B5]-[@B8]\], is hampered by the tolerance of surrounding normal tissues that must be respected if a favourable therapeutic ratio is to be maintained. Under such circumstances, simultaneous administration of radiosensitizing agents that increase tumour cell kill might improve the therapeutic ratio, provided these agents do not sensitize critical normal tissues in the same fashion. Moreover, radiation dose escalation does not address the issue of distant or out-of-field relapses. Based on the fact that the epidermal growth factor receptor (EGFR) is often over-expressed or mutated in NSCLC, the impact of such changes on cellular responses to ionising radiation has been explored \[[@B9]-[@B11]\]. Several drugs interfering with the EGFR signalling pathway have been developed, e.g. cetuximab, a human-murine chimeric IgG1 monoclonal antibody that binds to the extracellular region of the EGFR. Under experimental laboratory conditions in animal models, cetuximab increases tumour radiocurability (fractionated and single dose irradiation) \[[@B12],[@B13]\]. Clinically, this effect has been confirmed in head and neck cancer (phase III data with fractionated irradiation) \[[@B14]\]. Recently, initial clinical trials of cetuximab and RT for NSCLC have been completed, which are reviewed here in order to guide the development of the next generation of larger prospective studies. The data included in this review were identified by comprehensive searches of the PubMed database with combinations of the keywords \"NSCLC, RT, cetuximab, EFGR\" (last access August 15, 2011) and the reference lists of articles.

Cetuximab in patients who are not candidates for chemoradiation
---------------------------------------------------------------

As summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, two different phase II trials have studied combined RT and cetuximab without any chemotherapy \[[@B15],[@B16]\]. In the US trial, cetuximab was given concomitant to 60 Gy RT \[[@B15]\]. In the German trial, intensity-modulated RT to a total dose of 66 Gy was combined with concomitant and 13 weekly consolidation cycles of cetuximab \[[@B16]\]. Another important difference is that positron emission tomography (PET) was mandatory in the German trial, which also included patients with slightly more favourable baseline prognostic factors (some stage II patients, no weight loss \> 5%, younger median age). Median survival and response rates were higher in the German trial. However, such differences might result from treatment itself or inclusion of prognostically better patients. Mucosal and pulmonary toxicities occurred at the expected frequencies in patients irradiated for stage III NSCLC (elective nodal irradiation (ENI) was part of the treatment concept) but overall compliance and tolerability suggest that concomitant cetuximab and standard dose RT (60-66 Gy) is feasible even in patients unfit for chemoradiation. The median survival of 15.1 and 19.6 months respectively compares favourably with trials of comparable RT alone, e.g. the series of 127 patients reported by Jeremic et al. who found a median survival of 12 months \[[@B17]\], and the series of 106 patients reported by Wang et al. where median survival was 7.4 months \[[@B18]\]. However, such inter-study comparison might be hampered by several sources of bias (patient selection, improved staging, improved RT delivery etc.) and can not prove the superiority of combined treatment. Randomised comparison of RT alone and RT with cetuximab is still necessary. It would also be interesting to study whether irradiation to 60-66 Gy plus cetuximab is better than dose-escalated RT without cetuximab, given the high cost resulting from drug treatment.

###### 

Study design and efficacy

  Reference                        Study type                                       Patients                                                                                                            Other criteria                                                                                         RT schedule                                                                                                           Systemic therapy                                                                                                                         Follow-up      Results
  -------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Jensen et al. \[[@B16]\]         Single institution phase II, Germany, n = 30     Not candidates for concomitant chemoradiation (or refused), KPS at least 70, one of two trials with mandatory PET   Stage IIIA or B, no malignant pleural effusion, FEV1 ≥ 1.5 l or 40% of norm value, weight loss \< 5%   Only IMRT trial, 66 Gy in 33 daily fractions of 2 Gy, ENI to 50 Gy (or 40 depending on lung dose, target volume NR)   Cetuximab SR followed by 13 weekly consolidation cycles                                                                                  Median 19 mo   Median OS 19.6 mo, median PFS 8.5 mo, 63% PR, no CR, patterns of failure NR, survival not influenced by histology
  Jatoi et al. \[[@B15]\]          Multi-centre phase II, US, n = 58                Not candidates for concomitant chemoradiation, either age ≥ 65 years with ECOG 0-2 or younger but ECOG 2            Stage III A or B, no pleural effusion, FEV1 ≥ 1 l, haemoglobin ≥ 9 g/dl, V20 not exceeding 40%         60 Gy in 30 daily fractions of 2 Gy, ENI to ipsilateral hilar and mediastinal nodes (44 Gy)                           Cetuximab SR                                                                                                                             Median 17 mo   Median OS 15.1 mo, median PFS 7.2 mo, 26% PR, no CR, patterns of failure and impact of histology NR
  Hallqvist et al. \[[@B19]\]      Multi-centre phase II, Sweden, n = 71            Medically inoperable or unresectable, WHO 0-1                                                                       Stage IIIA or B, no pleural effusion with positive cytology, FEV1 ≥ 1 l or 40% of expected volume      68 Gy in 34 daily fractions of 2 Gy, no ENI                                                                           2 cycles of induction cisplatin/docetaxel, cetuximab SR starting one week before RT                                                      Median 39 mo   Median OS 17 mo, PFS NR, 16% PR and 7% CR at 12 months (NR at earlier time points), patterns of failure: 31% distant only, 23% local only, 7% regional only, 11% combinations of these, survival not influenced by histology
  Hughes et al. \[[@B20]\]         Dual centre phase II, UK, n = 12                 Inoperable, WHO 0-1                                                                                                 Stage IIIA or B, no pleural effusion                                                                   64 Gy in 32 fractions of 2 Gy, in 4 cases ENI to ipsilateral hilar and mediastinal nodes (50 Gy)                      Up to 4 cycles (median 3) of platinum-based induction CTx, cetuximab SR starting one week before RT                                      Median 10 mo   Median OS NR, PFS NR, 58% PR, no CR, patterns of failure and impact of histology NR
  Blumenschein et al. \[[@B21]\]   Multi-centre phase II, US, n = 87                Inoperable, Zubrod 0-1                                                                                              Stage IIIA or B, weight loss \< 5%, FEV1 ≥ 1,2 l                                                       63 Gy in 35 fractions of 1.8 Gy, ENI to ipsilateral hilar and mediastinal nodes (45 Gy)                               Cetuximab SR week 1-17, weekly carboplatin/paclitaxel during RT followed by 2 cycles consolidation carboplatin/paclitaxel                Median 22 mo   Median OS 22.7 mo, median time to progression around 14-15 mo, 29% CR, 33% PR, patterns of failure and impact of histology NR
  Govindan et al. \[[@B23]\]       Multi-centre phase II, randomised, US, n = 101   Inoperable, ECOG 0-1, one of two trials with mandatory PET                                                          Stage IIIA or B, no pleural effusion, weight loss ≤ 10%                                                70 Gy in 35 fractions of 2 Gy, no ENI                                                                                 Cetuximab SR (7 weeks) plus 4 cycles carboplatin/pemetrexed vs. same CTx without cetuximab (n = 48), afterwards 4 cycles of pemetrexed   Median 32 mo   Median OS 25.2 mo\*, median failure-free survival 12.3 mo, 4% CR, 68% PR, patterns of failure NR, survival not influenced by histology

RT: radiotherapy; IMRT: intensity-modulated radiotherapy; CTx: chemotherapy; KPS: Karnofsky performance status; ECOG: Eastern Cooperative Oncology Group performance status; WHO: World Health Organisation performance status; FEV1: forced expiratory volume 1; V20: lung volume receiving 20 Gy; ENI: elective nodal irradiation; Cetuximab SR: standard regimen with 400 mg/m^2^given i.v. on day 1 and 250 mg/m^2^on days 8, 15, 22, 29, 36 and 43; OS: overall survival; PFS: progression-free survival; PR and CR: partial and complete remission as per RECIST criteria; NR: not reported; PET: positron emission tomography

\* all results relate to the cetuximab arm of the study

###### 

Baseline characteristics and adverse events (AE)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                        Median age           Performance status   Stage        Weight loss                  Histology                   Adverse events (AE)
  -------------------------------- -------------------- -------------------- ------------ ---------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Jensen et al. \[[@B16]\]         71 years (57-82)     NR                   II: 7%\      Weight loss \< 5% required   Adenocarcinoma: 33%\        10% died before completing protocol treatment (death unlikely related to treatment), 50% had ≥ grade 3 non-hematologic AE
                                                                             IIIA: 57%\                                Squamous: 57%\              
                                                                             IIIB: 37%                                 Other or unknown: 10%       

  Jatoi et al. \[[@B15]\]          77 years (60-87)     0: 22%\              IIIA: 59%\   NR                           Adenocarcinoma: 38%\        No treatment-related deaths, 9% stopped early because of AE, 53% had at least one AE ≥ grade 3
                                                        1: 57%\              IIIB: 41%                                 Squamous: 43%\              
                                                        2: 21%                                                         Other or unspecified: 19%   

  Hallqvist et al. \[[@B19]\]      62 years (42-81)     0: 62%\              IIIA: 37%\   \> 5%: 37%                   Adenocarcinoma: 49%\        One pneumonitis-related death, 18% did not complete cetuximab and 11% received \< 68 Gy, 43% AE ≥ grade 3
                                                        1: 38%               IIIB: 63%                                 Squamous: 39%\              
                                                                                                                       Unspecified: 12%            

  Hughes et al. \[[@B20]\]         67.5 years (58-76)   0: 42%\              IIIA: 33%\   NR                           Adenocarcinoma: 33%\        One pneumonia-related death, 17% did not complete cetuximab, 17% AE ≥ grade 3
                                                        1: 58%               IIIB: 50%\                                Squamous: 50%\              
                                                                             IV: 17%                                   Other or unspecified: 17%   

  Blumenschein et al. \[[@B21]\]   64 years (42-85)     0: 47%\              IIIA: 46%\   Weight loss \< 5% required   NR                          6 treatment-related deaths, 20% did not complete RT and concurrent cetuximab, 68% had ≥ grade 3 non-hematologic AE
                                                        1: 53%               IIIB: 54%                                                             

  Govindan et al. \[[@B23]\]\*     66 years (32-81)     0: 34%\              IIIA: 53%\   Weight loss ≤ 10% required   Adenocarcinoma: 42%\        3 treatment-related deaths, 19% did not complete 4 cycles of CTx and 7 weeks of cetuximab, 62% had ≥ grade 3 non-hematologic AE and 70% ≥ grade 3 hematologic AE
                                                        1: 66%               IIIB: 47%                                 Squamous: 34%\              
                                                                                                                       Other or unspecified: 25%   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported; RT: radiotherapy

\*data shown are for patients in the cetuximab arm of this randomised study

Cetuximab and chemoradiation: induction chemotherapy only
---------------------------------------------------------

Two phase II studies have been published, as shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\[[@B19],[@B20]\]. Both included patients with inoperable stage III disease and good performance status. In the Swedish study, 2 cycles of induction cisplatin/docetaxel were administered \[[@B19]\]. The small UK study with a median of 3 cycles included patients treated with different regimens \[[@B20]\]. In both studies cetuximab was given concomitant to RT (total dose 64 and 68 Gy, respectively). ENI was administered to selected patients in the UK trial only. Serial computed tomography (CT) revealed that the UK trial included some patients with actual stage IV disease. Only the Swedish trial reported detailed outcome data. Median survival was 17 months, i.e. comparable to the results of the two trials without any chemotherapy \[[@B15],[@B16]\] or other studies of sequential chemotherapy and RT without cetuximab \[[@B18]\]. Toxicity and compliance were also comparable to these aforementioned studies. In the absence of randomised trials, these sparse data do not create enthusiasm about further studies of comparable approaches. It appears more attractive to put resources into trials of the other two categories reviewed here.

Cetuximab and chemoradiation: concomitant chemotherapy
------------------------------------------------------

The Radiation Therapy Oncology Group (RTOG) has recently published a phase II study of chemoradiotherapy with carboplatin and paclitaxel plus cetuximab in patients with stage III NSCLC \[[@B21]\]. From the loading dose of cetuximab to the end of the consolidation phase, 17 weekly treatments were administered. The radiation dose was 63 Gy in 35 fractions and chemotherapy was administered concurrently and in the consolidation phase. The authors concluded that treatment was feasible and survival longer than any previously reported by the RTOG. Median survival was 22.7 months. However, median time to progression was approximately 14-15 months (estimated from the graph). In other words, early cancer progression continues to be common. Moreover, RTOG trial 0117 reported median survival of 21.6 months in 44 patients with inoperable stage III NSCLC treated with 74 Gy and concomitant carboplatin/paclitaxel \[[@B22]\]. Median survival was numerically longer in the cetuximab trial but the absolute difference was 1 month. The second trial in this category was also completed in the US \[[@B23]\]. Several important differences exist (mandatory PET, higher radiation dose of 70 Gy, only 7 weeks of cetuximab concomitant to RT, chemotherapy with carboplatin and pemetrexed). Median survival was 25.2 months and failure-free survival 12.3 months. Given the large differences in study treatment, direct comparison appears difficult. It is important to mention that the two trials reviewed in this category reported higher rates of treatment-related deaths and adverse events than all the other studies where no concomitant chemotherapy was given. However, they also reported encouraging survival results, which led the investigators to initiate a confirmatory intergroup phase III trial that will clarify the role of additional cetuximab in this setting (RTOG 0617). Compared to other phase II studies without cetuximab, the survival results found in the two US trials are good but not exceptional. Table [3](#T3){ref-type="table"} contains a brief summary of relevant data, including selected arms from randomised trials, illustrating the possibility of impressive survival outcomes with quite different approaches. As mentioned previously, several sources of bias make comparisons between all these studies unreliable. Therefore, the present overview can not provide definitive recommendations.

###### 

Results of other recent chemoradiation trials, unresectable stage III (without cetuximab)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, patient number             Treatment                                                                                                         Median survival (PFS)
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------- -----------------------
  Bepler et al. \[[@B41]\], 39       2 cycles induction carboplatin and gemcitabine, RT up to 74 Gy (mean 70) with weekly carboplatin and paclitaxel   22.7 mo\
                                                                                                                                                       (14.3 mo)

                                                                                                                                                       

  Socinski et al. \[[@B42]\], 43     2 cycles induction carboplatin and paclitaxel, RT 74 Gy with weekly carboplatin and paclitaxel                    24.3 mo

                                                                                                                                                       

  Krzakowski et al. \[[@B43]\], 54   2 cycles induction cisplatin and vinorelbine, RT 66 Gy with 2 cycles cisplatin and vinorelbine                    23.4 mo\
                                                                                                                                                       (12.5 mo)

                                                                                                                                                       

  Sejpal et al. \[[@B44]\], 62       Weekly carboplatin and paclitaxel, RT median 74 Gy with protons                                                   24.4 mo

                                                                                                                                                       

  Segawa et al. \[[@B45]\], 99       RT 60 Gy with 4 cycles of concomitant cisplatin and docetaxel                                                     26.8 mo\
                                                                                                                                                       (13.4 mo)

                                                                                                                                                       

  Cho et al. \[[@B46]\], 49          Weekly carboplatin and paclitaxel, RT 60 Gy in 25 fractions                                                       28.1 mo\
                                                                                                                                                       (13.7 mo)

                                                                                                                                                       

  Gandara et al. \[[@B47]\], 83      RT 61 Gy with 2 cycles of concomitant cisplatin and etoposide, consolidation docetaxel                            26 mo\
                                                                                                                                                       (16 mo)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RT: radiotherapy; PFS: progression-free survival

Discussion
==========

Historically, the added value of cetuximab has been proven in a pivotal head and neck cancer radiotherapy trial, which did not include cytotoxic chemotherapy \[[@B14]\]. This trial confirmed preclinical results obtained in different in vitro and in vivo models \[[@B9]-[@B13]\]. The NSCLC studies reviewed in the present article suggest that conventional fractionated RT (3-D conformal or intensity-modulated) to a maximum dose of 70 Gy can safely be combined with cetuximab. With additional concomitant chemotherapy, toxicity increases to the high degree that has been observed in several studies of simultaneous chemoradiation without cetuximab \[[@B1],[@B4],[@B6]\]. Over 60% of patients developed ≥ grade 3 non-hematologic adverse events and comparable figures were reported for ≥ grade 3 hematologic adverse events, which contributed to the fact that approximately 20% of patients were unable to complete treatment \[[@B21],[@B23]\]. Importantly, no randomised head-to-head comparison of any of the 3 strategies reviewed here (RT plus cetuximab, induction chemotherapy followed by RT plus cetuximab, concomitant chemoradiation plus cetuximab) has yet been published. Therefore, both toxicity and efficacy results must be interpreted with caution. Non-randomised head and neck cancer studies suggested promising efficacy of combined cetuximab, RT and chemotherapy \[[@B24]-[@B26]\]. However, the phase III trial RTOG 0522 could not confirm improved progression-free or overall survival when cetuximab was added to RT with cisplatin \[[@B27]\]. Conflicting results have also been reported for rectal cancer \[[@B28]\].

This review does not attempt to provide treatment recommendations. Its purpose is to contribute to the development of future, large-scale prospective studies. Such studies seem warranted mainly in two settings 1) RT plus cetuximab in patients who can not tolerate chemoradiation, and 2) concomitant chemoradiation plus cetuximab in patients who qualify for such aggressive regimens. Regarding the latter approach, a randomised intergroup study based on the results of the RTOG trial \[[@B21]\] is under way. A question that will not be answered in this trial is the optimal duration of cetuximab treatment, provided there is a definitive benefit from this drug. As reviewed here, some groups chose to limit drug administration to the concomitant phase with RT while others continued cetuximab for longer durations. Given the cost of such treatment, the added value of extended cetuximab therapy must be proven in appropriate randomised settings. Other well recognised areas of controversy that apply to all NSCLC RT strategies including the cetuximab trials, are the role of ENI \[[@B7],[@B8],[@B29]\], PET for staging and treatment planning \[[@B8],[@B30]-[@B32]\], radiation dose escalation \[[@B8],[@B18],[@B22]\] and consolidation chemotherapy after chemoradiation \[[@B2],[@B33]\]. The variations in the 6 studies reviewed here nicely illustrate the uncertainties around these issues. None of these studies used accelerated RT regimens or hypofractionation in combination with cetuximab. However, altered fractionation RT resulting in shorter overall treatment time is one of the possibilities to improve NSCLC outcomes \[[@B34],[@B35]\].

Histology has gained increasing importance for the choice of NSCLC systemic therapy but had no significant influence on survival in the 3 cetuximab plus RT studies that looked at this parameter \[[@B16],[@B19],[@B23]\]. Whether these studies truly suggest that inclusion of any histologic type of NSCLC into future trials should be considered remains an open question, given their limited sample size and statistical power. However, individually tailored treatment has the potential to improve cost-effectiveness and spare patients from unnecessary toxicity. Unfortunately, at present no established biomarker or histology feature has gained widespread acceptance. A recent analysis of a phase III study (BMS099; taxane/carboplatin with or without cetuximab; no radiotherapy) where tumour samples from 225 patients were examined, did not find significant associations between KRAS and EGFR and various outcome parameters \[[@B36]\]. Also in the phase III FLEX study (cisplatin/vinorelbine with or without cetuximab; no radiotherapy) biomarkers (KRAS, EGFR, PTEN) did not predict treatment efficacy \[[@B37]\]. On the basis of all available data, it is not justified to exclude molecular subgroups of NSCLC from future RT and cetuximab studies. However, it is important to conduct additional biomarker analyses in these future studies. If EGFR inhibition increases the clinical efficacy of RT for stage III NSCLC, cetuximab might not be the only agent exerting this effect. Preliminary experience with tyrosine kinase inhibitors and thoracic RT has been published \[[@B38],[@B39]\]. However, these small non-randomised studies suffer from the same limitations as those reviewed here and have not provided definitive data. Because the presence of EGFR mutations in general is predictive of responsiveness to EGFR tyrosine kinase inhibitors, adenocarcinoma or NSCLC not otherwise specified should be tested for such alterations \[[@B40]\].

Conclusions
===========

The results of the 6 published clinical trials (none of them was a phase III study) suggest that larger randomised trials are warranted, primarily addressing the role of cetuximab with RT alone in patients unfit for chemoradiation and combined chemoradiation plus cetuximab in prognostically better patients. Correlative biomarker studies should be part of these research efforts.
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